Myelofibrosis A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of INCB050465 and ruxolitinib in subjects with myelofibrosis Talk to your doctor if you are interested in participating […]
Incyte conducts Phase 2 Clinical Trials for Myelofibrosis and Essential Thrombocythemia
June 15, 2017 By
MPN Clinical Trial updates from Geron and Promedior
November 6, 2014 By
Geron announces removal of Full Clinical Hold on Imetelstat The full clinical hold on Geron’s sole pipeline candidate, investigation new drug (IND), Imetelstat, has been lifted by the FDA. The company does not intend to conduct further studies or develop imetelstat for the treatment of essential thrombocythemia (ET) or polycythemia vera (PV). The development plan […]
Imetelstat Trials for MF moves forward as FDA removes hold
June 12, 2014 By
Geron Corp announced today that the partial clinical hold on clinical trials of imetelstat in myelofibrosis has been removed by the FDA. The hold for essential thrombocythemia and polycythemia vera remains. Click here for the full story.
Follow Us!